Madrigal Pharmaceuticals Inc. Common Stock (MDGL)

About MDGL

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

915

Website

www.madrigalpharma.com/

Fundamentals

1-day range

$528.42$542.78

Market cap

$11.79B

P/E (trailing)

—

P/E (forward)

56.12

EPS (trailing)

$-12.87

Dividend yield

—

Beta

-1.11

Avg. volume

364.2K

Dividend pay date

July 25, 2016

Forecasts

16 analyst ratings

Madrigal Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• MDGL

  Madrigal Pharmaceuticals Inc. Common Stock

  $534.12

  ▼ 1.76%
  Market cap $11.79BP/E —
  $393.61$615
• ELAN

  Elanco Animal Health Incorporated Common Stock

  $24.12

  ▼ 1.51%
  Market cap $12.09BP/E —
  $17.11$27.98
• ABVX

  Abivax SA American Depositary Shares

  $113.41

  ▼ 0.78%
  Market cap $11.19BP/E —
  $60.45$139
• AXSM

  Axsome Therapeutics Inc. Common Stock

  $199.01

  ▼ 3.52%
  Market cap $10.81BP/E —
  $112.9$260.19
• SMMT

  Summit Therapeutics Inc. Common Stock

  $13.71

  ▼ 4.33%
  Market cap $10.80BP/E —
  $12.07$29.23
• PRAX

  Praxis Precision Medicines Inc. Common Stock

  $344.95

  ▼ 6.23%
  Market cap $10.32BP/E —
  $37.19$392.7
• CYTK

  Cytokinetics Incorporated Common Stock

  $72.17

  ▼ 7.36%
  Market cap $10.13BP/E —
  $35.22$88.31

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
  Yahoo · 8/20/2026
• Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
  Yahoo · 8/19/2026
• This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold
  Benzinga · 8/17/2026
• Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands
  Yahoo · 8/15/2026
• Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
  Yahoo · 8/12/2026
• Madrigal Pharmaceuticals, Inc. (MDGL) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
  SeekingAlpha · 8/11/2026
• Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
  Yahoo · 8/6/2026
• Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
  Yahoo · 8/6/2026

• William John Sibold · July 20, 2026 · Sale

  280 @ $555.05
• William John Sibold · July 20, 2026 · Sale

  1 @ $550.72
• William John Sibold · July 20, 2026 · Sale

  153 @ $550.01
• William John Sibold · July 20, 2026 · Sale

  47 @ $548.87
• William John Sibold · July 20, 2026 · Sale

  680 @ $547.7
• William John Sibold · July 20, 2026 · Sale

  269 @ $547.08
• William John Sibold · July 20, 2026 · Sale

  275 @ $545.71
• William John Sibold · July 20, 2026 · Sale

  545 @ $544.71
• William John Sibold · July 20, 2026 · Sale

  110 @ $543.79
• William John Sibold · July 20, 2026 · Sale

  140 @ $542.75
• William John Sibold · July 17, 2026 · Option Exercise

  50.0K
• Rebecca Taub · June 17, 2026 · Grant

  766
• Rebecca Taub · June 17, 2026 · Grant

  454
• Richard S. Levy · June 17, 2026 · Grant

  766
• Richard S. Levy · June 17, 2026 · Grant

  454

Institutional Ownership

March 31, 2026

Total shares held

23.72M

Total value held

$12.09B

Institutional holders

375